An Analysis on HCV Treatment Efficacy among HIV/HCV Co-infected Patients
10.3969/j.issn.1003-4706.2018.05.024
- VernacularTitle:DAAs治疗HIV/HCV共感染患者HCV的疗效分析
- Author:
Shan-Qun GU
1
;
Zhong-Xi LI
;
Jin-Song BAI
;
Bo TIAN
;
Min YU
;
Jun LIU
Author Information
1. 昆明市第三人民医院感染科
- Keywords:
HIV/HCV co-infection;
DAAs;
HCV;
Treatment
- From:
Journal of Kunming Medical University
2018;39(5):120-123
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the efficacy and safety of DAAs in treating HCV patients with HIV/HCV co-infection.Method 53 patients were divided into groups based on HCV genotype. Sofosbuvir + Ledipasvir regime were used for 1b and 6a subtypes; sofosbuvir+Daclatasvir regime were used for 3a, 3b and those cannot be typed; all the patients diagnosed with cirrhosis were also administrated with ribavirin. The course of treatment for all patients is 12 weeks.Results All 53 patients completed HCV treatment, the overall SVR rate of DAAs treatment rate was 98.1%(52/53), failure rate 1.9%(1/53) ; SVR rate of DAAs treatment among non-cirrhosis patients was 100%(41/41) ; SVR rate of DAAs treatment among cirrhosis patients was 91.7%(11/12), failure rate 8.3%(1/11) . After treatment, ALT and AST levels of DAAs treatment patients were decreased (P＜0.05), while CD4 level increased (P＜0.05) . Main adverse effects are: 12 patients had gastrointestinal symptoms (22.6%) ; 6 had nausea, vomiting (11.3%), 4 had diarrhea (7.6%), 1 had mild rash (1.9%), and 5 had elevated serum total bilirubin (9.4%) . Conclusion The overall SVR rate among DAA treatment for HIV/HCV co-infected patients is high (98.1%) with broad indications. Even patients with cirrhosis are eligible. It yielded optimistic outcomes among different gene subtypes, and effectively improved liver function and CD4 level. With oral administration, short regime course, and mild adverse effects, patients can tolerate well, indicating its effectiveness and safety.
